An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease.
Clostridium difficile is an important cause of nosocomial morbidity and mortality and is implicated in recent epidemics. Data support the treatment of colitis with oral metronidazole in a dose of 1.0 to 1.5 g/d, with oral vancomycin as a second-line agent, not because its efficacy is questioned but because of environmental concerns. Nitazoxanide and other drugs are currently under intense study as alternatives. Treatment of asymptomatic patients is not recommended. Current management strategies appear to be increasingly ineffective, especially for patients who experience multiple recurrences. Biotherapy and vaccination are currently being explored as treatment options for patients who have recurrent disease. Greater attention should be paid to hospital infection control policies and restriction of broad-spectrum antibiotics.
Aslam
Saima
S
Medical Service (Infectious Disease Section), Michael E. DeBakey Veterans Affairs Medical Center, Room 4B-370, 2002 Holcombe Boulevard, Houston, TX 77030, USA. saslam@bcm.tmc.edu
Musher
Daniel M
DM
D016360:Clostridioides difficile; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans